IP Library › Granted Patent US 9,480,754
Granted Patent B2
US 9,480,754 · App. 15/099,789 · Granted Nov 1, 2016

Phospholipid ether analogs as cancer-targeting drug vehicles

Inventors: Jamey P. Weichert (Fitchburg, WI); Anatoly Pinchuk (Fitchburg, WI); Kevin Kozak (Madison, WI); Marc Longino (Verona, WI); Joseph Grudzinski (Madison, WI); Benjamin Titz (Madison, WI); Chorom Pak (Madison, WI); Nathan Stehle (Madison, WI)
Assignee: CELLECTAR BIOSCIENCES, INC.
A61K47/48053A61K31/00A61K31/337A61K31/395A61K31/537A61K31/665A61K47/48084
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,480,754
App. No.
15/099,789
Granted
Nov 1, 2016
Kind
B2
Abstract

The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.

Claims (4)

1. A method of treating breast cancer, lung cancer, pancreatic cancer, colorectal cancer, and/or prostate cancer comprising administering an effective amount of a therapeutic compound of Formula (V),

to a subject with cancer.

2. The method of claim 1 wherein the cancer comprises cancer stem cells.

3. The method of claim 1 wherein the cancer is recurrent.

Continuity (3)
Division 14934209 · Nov 6, 2015
Provisional Application 62080436 · Nov 17, 2014
Related Publication 20160228564A1 · Aug 11, 2016